Browsing Tag
tonlamarsen
2 posts
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
Kardigan’s tonlamarsen data put acute severe hypertension into sharper commercial focus
Kardigan’s tonlamarsen Phase 2 data showed blood pressure promise despite mixed endpoints. Read what it means for acute severe hypertension next.